G1 Therapeutics

Genor Biopharma Holdings Ltd. received China National Medical Products Administration (NMPA) approval for Lerociclib (GB491), a novel CDK4/6 inhibitor for advanced breast cancer treatment.

• The mTNBC pipeline includes over 12 drugs from 10+ companies, targeting novel approaches to improve treatment outcomes for this aggressive breast cancer. • Trilaciclib, a CDK4/6 inhibitor by G1 Therapeutics, is in Phase III trials to preserve bone marrow and immune function during chemotherapy in mTNBC patients. • Olinvacimab, an anti-angiogenic antibody by PharmAbcine/Merck, is in Phase II trials, blocking the VEGF/VEGFR2 pathway to inhibit tumor growth and metastasis. • Emerging therapies focus on intravenous, subcutaneous, and oral routes of administration, with molecule types including monoclonal antibodies and small molecules.

Danish pharmaceutical company Pharmacosmos has finalized its acquisition of US-based G1 Therapeutics, gaining ownership of the cancer drug Cosela in a deal valued at over half a billion kroner.

Pharmacosmos Group has successfully completed its acquisition of G1 Therapeutics for $7.15 per share, representing a 68% premium to G1's closing price before announcement and a total equity value of approximately $405 million.